ClinicalTrials.gg
TerminatedNCT06524739Updated Apr 13, 2026Results posted

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

A Phase 3 interventional study of IgPro20 and Placebo in Post-COVID Postural Orthostatic Tachycardia Syndrome, sponsored by CSL Behring. Terminated at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision, not for safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States — 19 open to participants now, 42 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · United States.

Enrollment
55th of 67
16 · median 36
Started
2024
with 7 others
Phase 3
2 of 92
none open now
Registered
80th of 92
by date

Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, this one is the 55th largest by enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2024, is one of 2 in phase 3, and was the 80th registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

19 of the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 [COVID-19] POTS [post-COVID-POTS]).

03

Conditions studied

  • Post-COVID Postural Orthostatic Tachycardia Syndrome

Keywords

  • POTS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written and be willing and, in the opinion of the investigator, able to adhere to all protocol requirements.
  2. Males and females aged ≥ 18 at the time of providing written informed consent.
  3. Diagnosis of post-COVID POTS, defined by both a preceding COVID-19 infection based on confirmed historical documentation and onset of POTS symptoms developing within 4 months after COVID-19 infection as defined per consensus criteria.
  4. COMPASS-31 score of at least 40 at the Screening visit.
  5. Positive confirmatory standardized standing test (ie, HR increase of ≥ 30 bpm [≥ 40 bpm for participants aged 18 to 19 years] within 10 minutes in the absence of orthostatic hypotension) at the Screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with Immunoglobulin G (IgG) or plasmapheresis within 12 weeks before Screening
  2. Symptoms and / or diagnosis of or receiving treatment for POTS before COVID-19 infection
  3. Prior diagnosis of or receiving current treatment at Screening for the following conditions (unless onset was related to the inciting POTS-associated COVID-19 infection): certain neurologic, , endocrine, cardiac, or other disorders, and pre-existing psychiatric disorders
  4. Presence of active infections, including infection, , , active SARS-CoV-2 infection, or any uncontrolled systemic infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    IgPro20

    Biological: IgPro20

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalIgPro20

    IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration

    Also known as: HIZENTRA®

  • BiologicalPlacebo

    2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants No Longer Meeting Diagnostic Criteria of Post-COVID POTS as Measured by Standardized Standing Test (ie, No Longer Experiencing HR Increase of ≥30 Bpm, in the Absence of 20 mmHg Decrease of SBP [Orthostatic Hypotension])

    The reported data reflect the percentage of participants who no longer met the diagnostic criteria for Post-Coronavirus Disease 2019 (COVID) Postural Orthostatic Tachycardia Syndrome (POTS), as assessed by a standardized standing test (i.e., no longer experiencing a heart-rate (HR) increase of \>=30 bpm in the absence of a 20 mmHg decrease in systolic blood pressure \[SBP; orthostatic hypotension\]), among participants evaluated at that visit. The Baseline data represent the proportion of participants who were meeting the diagnostic criteria for post-COVID POTS.

    Time frame: At Baseline and at Week 25

Secondary outcomes

  1. Change From Baseline in Orthostatic Intolerance (OI) Score of Composite Autonomic Symptom Score 31 (COMPASS-31)

    The COMPASS-31 was a self-reported questionnaire that measures autonomic symptoms across six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. The OI domain assesses symptoms including faintness, dizziness, feeling "goofy," or had difficulty thinking soon after standing up from a sitting or lying position, and generates a total score ranging from 0 to 40 with higher scores representing a higher symptom burden. The treatment effect of interest was the difference from baseline in OI score of COMPASS-31. A more negative change from baseline indicates a greater improvement in OI symptoms.

    Time frame: At Baseline and at Week 25

  2. Change From Baseline in COMPASS-31 Total Score

    The COMPASS-31 was a self-reported questionnaire that measured autonomic symptoms related to six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. This questionnaire generated a weighted score ranging from 0 to 100, with higher scores representing a higher symptom burden. A COMPASS-31 score of \>=40 indicated that participants had severe autonomic dysfunction. A more negative change from baseline indicates a greater improvement in autonomic symptoms.

    Time frame: At Baseline and at Week 25

  3. Change From Baseline in Heart Rate Increase Within 10 Minutes of Standing Test

    Heart rate for the standing test was measured at the end of 10 minutes in the supine position and at 1, 3, 5, 7, and 10 minutes of standing. The change in heart rate during the standing test was calculated as the difference between the average of the two highest heart rate measurements (bpm) within 10 minutes of standing and the heart rate measurement (bpm) at the end of 10 minutes in the supine position.

    Time frame: At Baseline and at Week 25

  4. Number of Participants With Treatment-Emergent Adverse Event (TEAE), Related TEAE, Serious TEAE and Related Serious TEAE

    Time frame: Up to Week 45

  5. Percentage of Participants With TEAE, Related TEAE, Serious TEAE and Related Serious TEAE

    The participant data were rounded to one decimal place.

    Time frame: Up to Week 45

  6. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Time frame: Up to Week 45

  7. Percentage of Participants With Clinically Significant ECG Abnormalities

    Time frame: Up to Week 45

  8. Number of Participants With Change From Baseline in Clinically Significant ECG Abnormalities

    Time frame: From Baseline up to Week 45

  9. Percentage of Participants With Change From Baseline in Clinically Significant ECG Abnormalities

    Time frame: From Baseline up to Week 45

07

Results

Posted Apr 13, 2026
Limitations and caveats
The study was permanently terminated early by the sponsor because of recruitment difficulties due to stringent eligibility criteria relating to the participant's acute COVID-19 infection. Fewer than 10% of the planned number of participants were enrolled in the study and, consequently, no efficacy conclusions can be drawn due to the limited sample size and the fact that the premature discontinuation occurred at different study visits.

Participant flow

This study was conducted in the United States.

Double-blind Period (Period 1)
Participant flow — Double-blind Period (Period 1)
MilestoneIgPro20/IgPro20Placebo/IgPro20
Started115
Completed30
Not completed85
Withdrew: Study terminated by sponsor85
Open-label Period (Period 2)
Participant flow — Open-label Period (Period 2)
MilestoneIgPro20/IgPro20Placebo/IgPro20
Started30
Completed00
Not completed30
Withdrew: Study terminated by sponsor30

Outcome measures

PrimaryProportion of Participants No Longer Meeting Diagnostic Criteria of Post-COVID POTS as Measured by Standardized Standing Test (ie, No Longer Experiencing HR Increase of ≥30 Bpm, in the Absence of 20 mmHg Decrease of SBP [Orthostatic Hypotension])

The reported data reflect the percentage of participants who no longer met the diagnostic criteria for Post-Coronavirus Disease 2019 (COVID) Postural Orthostatic Tachycardia Syndrome (POTS), as assessed by a standardized standing test (i.e., no longer experiencing a heart-rate (HR) increase of \>=30 bpm in the absence of a 20 mmHg decrease in systolic blood pressure \[SBP; orthostatic hypotension\]), among participants evaluated at that visit. The Baseline data represent the proportion of participants who were meeting the diagnostic criteria for post-COVID POTS.

Time frame:
At Baseline and at Week 25
Reported as:
Number · Percentage of participants
Proportion of Participants No Longer Meeting Diagnostic Criteria of Post-COVID POTS as Measured by Standardized Standing Test (ie, No Longer Experiencing HR Increase of ≥30 Bpm, in the Absence of 20 mmHg Decrease of SBP [Orthostatic Hypotension])
Percentage of participantsIgPro20 (Double-blind Period)Placebo (Double-blind Period)
At Baseline100100
At Week 2533.3—
SecondaryChange From Baseline in Orthostatic Intolerance (OI) Score of Composite Autonomic Symptom Score 31 (COMPASS-31)

The COMPASS-31 was a self-reported questionnaire that measures autonomic symptoms across six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. The OI domain assesses symptoms including faintness, dizziness, feeling "goofy," or had difficulty thinking soon after standing up from a sitting or lying position, and generates a total score ranging from 0 to 40 with higher scores representing a higher symptom burden. The treatment effect of interest was the difference from baseline in OI score of COMPASS-31. A more negative change from baseline indicates a greater improvement in OI symptoms.

Time frame:
At Baseline and at Week 25
Reported as:
Mean · Score on a scale
Change From Baseline in Orthostatic Intolerance (OI) Score of Composite Autonomic Symptom Score 31 (COMPASS-31)
Score on a scaleIgPro20 (Double-blind Period)Placebo (Double-blind Period)
Change From Baseline in Orthostatic Intolerance (OI) Score of Composite Autonomic Symptom Score 31 (COMPASS-31)-25.3 ± 10.07—
SecondaryChange From Baseline in COMPASS-31 Total Score

The COMPASS-31 was a self-reported questionnaire that measured autonomic symptoms related to six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. This questionnaire generated a weighted score ranging from 0 to 100, with higher scores representing a higher symptom burden. A COMPASS-31 score of \>=40 indicated that participants had severe autonomic dysfunction. A more negative change from baseline indicates a greater improvement in autonomic symptoms.

Time frame:
At Baseline and at Week 25
Reported as:
Mean · Score on a scale
Change From Baseline in COMPASS-31 Total Score
Score on a scaleIgPro20 (Double-blind Period)Placebo (Double-blind Period)
Change From Baseline in COMPASS-31 Total Score-46.65 ± 6.014—
SecondaryChange From Baseline in Heart Rate Increase Within 10 Minutes of Standing Test

Heart rate for the standing test was measured at the end of 10 minutes in the supine position and at 1, 3, 5, 7, and 10 minutes of standing. The change in heart rate during the standing test was calculated as the difference between the average of the two highest heart rate measurements (bpm) within 10 minutes of standing and the heart rate measurement (bpm) at the end of 10 minutes in the supine position.

Time frame:
At Baseline and at Week 25
Reported as:
Mean · Beats per minute
Change From Baseline in Heart Rate Increase Within 10 Minutes of Standing Test
Beats per minuteIgPro20 (Double-blind Period)Placebo (Double-blind Period)
Change From Baseline in Heart Rate Increase Within 10 Minutes of Standing Test-13.25 ± 6.718—
SecondaryNumber of Participants With Treatment-Emergent Adverse Event (TEAE), Related TEAE, Serious TEAE and Related Serious TEAE
Time frame:
Up to Week 45
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Event (TEAE), Related TEAE, Serious TEAE and Related Serious TEAE
ParticipantsIgPro20 (Double-blind Period)Placebo (Double-blind Period)IgPro20 (Open-label Period)
Any TEAE1040
Any TEAE Related to Study Treatment900
Any Serious TEAE000
Any Serious TEAE Related to Study Treatment000
SecondaryPercentage of Participants With TEAE, Related TEAE, Serious TEAE and Related Serious TEAE

The participant data were rounded to one decimal place.

Time frame:
Up to Week 45
Reported as:
Number · Percentage of participants
Percentage of Participants With TEAE, Related TEAE, Serious TEAE and Related Serious TEAE
Percentage of participantsIgPro20 (Double-blind Period)Placebo (Double-blind Period)IgPro20 (Open-label Period)
Any TEAE90.980.00
Any TEAE Related to Study Treatment81.800
Any Serious TEAE000
Any Serious TEAE Related to Study Treatment000
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Time frame:
Up to Week 45
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsIgPro20 (Double-blind Period)Placebo (Double-blind Period)IgPro20 (Open-label Period)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities000
SecondaryPercentage of Participants With Clinically Significant ECG Abnormalities
Time frame:
Up to Week 45
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant ECG Abnormalities
Percentage of participantsIgPro20 (Double-blind Period)Placebo (Double-blind Period)IgPro20 (Open-label Period)
Percentage of Participants With Clinically Significant ECG Abnormalities000
SecondaryNumber of Participants With Change From Baseline in Clinically Significant ECG Abnormalities
Time frame:
From Baseline up to Week 45
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Clinically Significant ECG Abnormalities
ParticipantsIgPro20 (Double-blind Period)Placebo (Double-blind Period)IgPro20 (Open-label Period)
Number of Participants With Change From Baseline in Clinically Significant ECG Abnormalities000
SecondaryPercentage of Participants With Change From Baseline in Clinically Significant ECG Abnormalities
Time frame:
From Baseline up to Week 45
Reported as:
Number · Percentage of participants
Percentage of Participants With Change From Baseline in Clinically Significant ECG Abnormalities
Percentage of participantsIgPro20 (Double-blind Period)Placebo (Double-blind Period)IgPro20 (Open-label Period)
Percentage of Participants With Change From Baseline in Clinically Significant ECG Abnormalities000

Adverse events

Collected over Up to Week 45. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IgPro20 (Double-blind Period)0/11 (0%)0/11 (0%)10/11 (90.9%)
Placebo (Double-blind Period)0/5 (0%)0/5 (0%)4/5 (80%)
IgPro20 (Open-label Period)0/3 (0%)0/3 (0%)0/3 (0%)
Most frequent other events
Showing 10 of 33
Most frequent other events
EventIgPro20 (Double-blind Period)Placebo (Double-blind Period)IgPro20 (Open-label Period)
Infusion site painGeneral disorders3/111/50/3
Injection site painGeneral disorders3/110/50/3
FatigueGeneral disorders0/111/50/3
Infusion site haemorrhageGeneral disorders0/111/50/3
HeadacheNervous system disorders2/111/50/3
Balance disorderNervous system disorders0/111/50/3
DizzinessNervous system disorders0/111/50/3
Neuropathy peripheralNervous system disorders0/111/50/3
Grip strength decreasedInvestigations0/111/50/3
BronchitisInfections and infestations0/111/50/3

Baseline characteristics

The Intention-to-Treat (ITT) analysis set included all participants in the Screened Analysis Set (SAS) who were randomized into the study.

Age, Categorical
Age, Categorical(Participants)IgPro20/IgPro20Placebo/IgPro20Total
<=18 years000
Between 18 and 65 years11516
>=65 years000
Age, Continuous
Age, Continuous(Years)IgPro20/IgPro20Placebo/IgPro20Total
Mean31.2 ± 8.7837.8 ± 8.4733.3 ± 8.98
Sex: Female, Male
Sex: Female, Male(Participants)IgPro20/IgPro20Placebo/IgPro20Total
Female7411
Male415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IgPro20/IgPro20Placebo/IgPro20Total
Hispanic or Latino101
Not Hispanic or Latino9514
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IgPro20/IgPro20Placebo/IgPro20Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White11314
More than one race000
Unknown or Not Reported000
08

Study locations

38 sites
  • University of Alabama Hospital at Birmingham
    Birmingham, Alabama 35294-1152, United States
  • Center for Complex Neurology, EDS & POTS
    Phoenix, Arizona 85006, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Arkansas Cardiology Clinic - Little Rock
    Little Rock, Arkansas 72205, United States
  • UC San Diego Health
    La Jolla, California 92037, United States
  • University of california Irvine
    Orange, California 92868, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Hope Research Network
    Miami, Florida 33166, United States
  • Well Pharma Medical Research, Corp
    Miami, Florida 33173, United States
  • Velocity Clinical Research, Savannah
    Savannah, Georgia 31406, United States
  • LSU Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Velocity Clinical Research, Metairie
    New Orleans, Louisiana 70119, United States
  • Johns Hopkins Bayview Medical Center PMR
    Baltimore, Maryland 21224, United States
  • Mass General Brigham (Massachusetts General Hospital)
    Belmont, Massachusetts 02478, United States
  • Profound Research LLC at Millennium Affiliated Physicians
    Farmington Hills, Michigan 48334, United States
  • Velocity Clinical Research - Lincoln
    Lincoln, Nebraska 68510, United States
  • Dysautonomia Clinic
    Buffalo, New York 14221, United States
  • NYU Langone Health South Shore Neurologic Associates
    Patchogue, New York 11772, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Bernstein Clinical Research Center
    Cincinnati, Ohio 45236, United States
  • University Hospital Cleveland Medical Center
    Cleveland, Ohio 44195, United States
  • Hightower Clinical
    Oklahoma City, Oklahoma 73134, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Velocity Clinical Research - Union
    Union, South Carolina 29379, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • UT Austin Dell Medical School
    Austin, Texas 78712, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • Sunbeam Clinical Research
    McKinney, Texas 75069, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Bateman Horne Center
    Salt Lake City, Utah 84102, United States
  • Metrodora Institute
    West Valley City, Utah 84119, United States
  • Velocity Clinical Research - Hampton
    Hampton, Virginia 23666, United States
  • VCU Health
    Richmond, Virginia 23219, United States
  • Libin Cardiovascular Institute University of Calgary
    Calgary, T2N 4Z6, Canada
  • University of Alberta Hospital
    Edmonton, T6G 2B7, Canada
  • McGill University Health Centre
    Québec, H4A 3J1, Canada
  • Ciussse-Chus
    Sherbrooke, J1H 5N4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Jun 2025, 9 months.

Results were first posted in Apr 2026, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2024
First posted
Jul 29, 2024
StartActual
Aug 28, 2024
Primary completionActual
Jun 20, 2025
CompletionActual
Jul 11, 2025
Results first posted
Apr 13, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06524739
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Aug 28, 2024
Primary completion
Jun 20, 2025
Completion
Jul 11, 2025
Results posted
Apr 13, 2026
Last update
Apr 13, 2026

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hizentra

Start the discussion